Drug Profile


Alternative Names: ATI-7505

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Renexxion
  • Class Benzamides; Gastrokinetics; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Gastro-oesophageal reflux; Non-ulcer dyspepsia
  • Discontinued Erosive oesophagitis

Most Recent Events

  • 19 Jul 2018 Renexxion grants Sinovant Sciences an exclusive license for the development and commercialise Naronapride in China, Hong Kong, Macau and Taiwan for gastrointestinal disorders
  • 19 Jul 2018 Efficacy and adverse events data from a phase II trial in Chronic idiopathic constipation released by Sinovant Sciences
  • 16 Nov 2016 Renexxion plans two phase III trials for Constipation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top